Medtronic to Buy SPR Therapeutics for About $650 Million
By Colin Kellaher
Medtronic has agreed to buy privately held medical-technology company SPR Therapeutics for about $650 million in cash in a deal that bolsters its neuromodulation portfolio.
Medtronic on Wednesday said the deal adds SPR's Sprint peripheral-nerve-stimulation system, a short-term, 60-day therapy designed to provide pain relief through a temporary treatment approach that doesn't require a permanent implant.
The Galway, Ireland-based medical-technology company said it expects to complete the acquisition in the first half of its 2027 fiscal year, which began on April 25.
Medtronic last month completed the acquisition of CathWorks, a medical-device company focused on cardiovascular disease, in a deal valued at $585 million and in March agreed to buy Scientia Vascular in a $550 million deal that adds to its neurovascular portfolio.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 20, 2026 09:49 ET (13:49 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States